DANONE (BSN.DE) Stock Fundamental Analysis
Europe - FRA:BSN - FR0000120644 - Common Stock
77.24 EUR
+0.24 (+0.31%)
BSN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 59 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are some minor concerns on its financial health. BSN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BSN had positive earnings in the past year.
In the past year BSN had a positive cash flow from operations.
BSN had positive earnings in each of the past 5 years.
Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.20%, BSN is in line with its industry, outperforming 59.32% of the companies in the same industry.
BSN has a Return On Equity of 11.59%. This is in the better half of the industry: BSN outperforms 64.41% of its industry peers.
BSN has a better Return On Invested Capital (6.83%) than 62.71% of its industry peers.
BSN had an Average Return On Invested Capital over the past 3 years of 6.38%. This is in line with the industry average of 7.26%.
The last Return On Invested Capital (6.83%) for BSN is above the 3 year average (6.38%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
With a decent Profit Margin value of 6.72%, BSN is doing good in the industry, outperforming 74.58% of the companies in the same industry.
BSN's Profit Margin has been stable in the last couple of years.
With an excellent Operating Margin value of 13.25%, BSN belongs to the best of the industry, outperforming 81.36% of the companies in the same industry.
In the last couple of years the Operating Margin of BSN has declined.
Looking at the Gross Margin, with a value of 50.47%, BSN is in the better half of the industry, outperforming 79.66% of the companies in the same industry.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
BSN has more shares outstanding than it did 1 year ago.
BSN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BSN has an improved debt to assets ratio.
2.2 Solvency
BSN has an Altman-Z score of 2.55. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.55, BSN is in the better half of the industry, outperforming 61.02% of the companies in the same industry.
BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 5.07, BSN is in the better half of the industry, outperforming 69.49% of the companies in the same industry.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
The Debt to Equity ratio of BSN (0.83) is worse than 66.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.55 |
ROIC/WACC1.05
WACC6.51%
2.3 Liquidity
BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
BSN's Current ratio of 0.95 is on the low side compared to the rest of the industry. BSN is outperformed by 72.88% of its industry peers.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
BSN has a Quick ratio of 0.78. This is comparable to the rest of the industry: BSN outperforms 42.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 4.47% over the past year.
BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
The Revenue has been growing slightly by 0.54% in the past year.
Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
The Earnings Per Share is expected to grow by 6.84% on average over the next years.
BSN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.24% yearly.
EPS Next Y7.65%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
EPS Next 5Y6.84%
Revenue Next Year0.54%
Revenue Next 2Y1.69%
Revenue Next 3Y2.42%
Revenue Next 5Y3.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 20.65, the valuation of BSN can be described as rather expensive.
BSN's Price/Earnings is on the same level as the industry average.
BSN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.19, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 18.64 indicates a rather expensive valuation of BSN.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BSN indicates a slightly more expensive valuation: BSN is more expensive than 62.71% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.50, BSN is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.65 | ||
| Fwd PE | 18.64 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BSN is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.34 | ||
| EV/EBITDA | 11.09 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.7
PEG (5Y)N/A
EPS Next 2Y6.85%
EPS Next 3Y7.31%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.75%. Purely for dividend investing, there may be better candidates out there.
BSN's Dividend Yield is comparable with the industry average which is at 3.32.
BSN's Dividend Yield is comparable with the S&P500 average which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.75% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
BSN pays out 74.99% of its income as dividend. This is not a sustainable payout ratio.
The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP74.99%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
FRA:BSN (10/30/2025, 7:00:00 PM)
77.24
+0.24 (+0.31%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners55.49%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap52.63B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target78.66 (1.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.75% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.72%
PT rev (3m)3.71%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.33%
Revenue NY rev (3m)-1.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.65 | ||
| Fwd PE | 18.64 | ||
| P/S | 1.92 | ||
| P/FCF | 18.34 | ||
| P/OCF | 13.68 | ||
| P/B | 3.32 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.09 |
EPS(TTM)3.74
EY4.84%
EPS(NY)4.14
Fwd EY5.37%
FCF(TTM)4.21
FCFY5.45%
OCF(TTM)5.64
OCFY7.31%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.7
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.55 |
F-Score8
WACC6.51%
ROIC/WACC1.05
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.65%
EPS Next 2Y6.85%
EPS Next 3Y7.31%
EPS Next 5Y6.84%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.54%
Revenue Next 2Y1.69%
Revenue Next 3Y2.42%
Revenue Next 5Y3.24%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.38%
EBIT Next 3Y14.38%
EBIT Next 5Y10.86%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 4 / 10 to BSN.DE.
What is the valuation status of DANONE (BSN.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 6 / 10.
What are the PE and PB ratios of DANONE (BSN.DE) stock?
The Price/Earnings (PE) ratio for DANONE (BSN.DE) is 20.65 and the Price/Book (PB) ratio is 3.32.
Can you provide the expected EPS growth for BSN stock?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.65% in the next year.